Table 1 Characteristics of study participants.

From: Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level

 

HCC (n = 96)

Hepatitis (n = 40)

LC (n = 30)

P-value

Age, mean ± SD, years

60 ± 11

47 ± 16

60 ± 10

 < 0.0001

Gender, n (%)

   

0.0053

Male

69 (72%)

17 (43%)

19 (63%)

 

Female

27 (28%)

23 (58%)

11 (37%)

 

Etiology, n (%)

    

HBV

68 (71%)

38 (95%)

19 (63%)

 

HCV

27 (28%)

2 (5%)

10 (33%)

 

HBV + HCV

0

0

1 (3%)

 

Cryptogenic

1 (1%)

0

0

 

Laboratory tests

    

AST (U/L)

80 ± 88

35 ± 41

37 ± 27

0.001

ALT (U/L)

57 ± 51

47 ± 78

35 ± 29

0.1475

Cirrhosis, n (%)

86 (90%)

NA

30 (100%)

 

Tumor stage

 

NA

NA

NA

BCLC stage 0 (Very early)

11 (11%)

   

BCLC stage A (Early)

31 (32%)

   

BCLC stage B (Intermediate)

28 (29%)

   

BCLC stage C (Advanced)

21 (22%)

   

BCLC stage D (Terminal)

5 (5%)

   
  1. ALT alanine aminotransferase, AST aspartate aminotransferase, BCLC Barcelona Clinic Liver Cancer, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, LC liver cirrhosis, NA not applicable, SD standard deviation.
Back to article page